Overview
- Under the agreements, cash prices via TrumpRx for injectable GLP‑1s will average about $350 per month, Medicare and Medicaid will pay roughly $245 per month, and eligible Medicare patients will face a $50 monthly copay.
- Starting‑dose oral GLP‑1 pills are slated at $149 per month if approved, while some injection doses will be higher than entry pricing, with Lilly listing Zepbound from $299 to $449 depending on strength.
- Medicare Part D coverage will launch through a pilot targeted for mid‑2026 that is designed to reach most beneficiaries, Medicaid discounts will depend on state opt‑ins, and TrumpRx is planned to go live by January 2026.
- The package includes three years of tariff relief for the manufacturers, and Novo Nordisk warned of a direct, negative low single‑digit impact on 2026 global sales growth as stocks of both companies slipped after the news.
- Key elements remain unresolved, including final pilot rules, eligibility constraints for weight‑loss use under Medicare law, and pricing tied to products such as oral pills and new multidose pens that have not yet received FDA approval.